TY - JOUR
T1 - Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs
AU - Miyata, Hiroshi
AU - Yamasaki, Makoto
AU - Kurokawa, Yukinori
AU - Takiguchi, Shuji
AU - Nakajima, Kiyokazu
AU - Fujiwara, Yoshiyuki
AU - Mori, Masaki
AU - Doki, Yuichiro
PY - 2012/9/15
Y1 - 2012/9/15
N2 - Background and Objectives There is no consensus on treatment for esophageal cancer invading adjacent organs (T4), but induction multidrug chemotherapy may be a beneficial, especially when surgery is considered as adjuvant treatment. Methods We classified 169 patients with T4 esophageal cancer without distant metastasis into those undergoing chemotherapy using cisplatin and 5-FU (CF) plus adriamycin or CF plus docetaxel (79 patients) and those undergoing chemoradiotherapy using CF (90 patients). For the former group, chemoradiation was subsequently applied when surgical resection was not indicated. Results Thirty-four patients in the chemotherapy group (43.0%) received chemoradiotherapy following chemotherapy. Although the response rate tended to be higher in the chemoradiotherapy group, there was no significant difference in the response rate between the groups (63.3% vs. 68.9%). Esophageal perforation during treatment was more frequent among the chemoradiotherapy group than the chemotherapy group (16.7% vs. 6.3%, Pa=0.0379). The rate of surgical resection was consequently higher for the induction chemotherapy group compared to the chemoradiotherapy group (72.1% vs. 45.6%, P=0.0005). Conclusions Induction triplet chemotherapy reduced esophageal perforation and increased the resectability of T4 esophageal cancers by combining second-line chemoradiotherapy. This strategy might increase the chance of curative resection for patients with T4 esophageal cancer. J. Surg. Oncol. 2012; 106:441-447. © 2012 Wiley Periodicals, Inc.
AB - Background and Objectives There is no consensus on treatment for esophageal cancer invading adjacent organs (T4), but induction multidrug chemotherapy may be a beneficial, especially when surgery is considered as adjuvant treatment. Methods We classified 169 patients with T4 esophageal cancer without distant metastasis into those undergoing chemotherapy using cisplatin and 5-FU (CF) plus adriamycin or CF plus docetaxel (79 patients) and those undergoing chemoradiotherapy using CF (90 patients). For the former group, chemoradiation was subsequently applied when surgical resection was not indicated. Results Thirty-four patients in the chemotherapy group (43.0%) received chemoradiotherapy following chemotherapy. Although the response rate tended to be higher in the chemoradiotherapy group, there was no significant difference in the response rate between the groups (63.3% vs. 68.9%). Esophageal perforation during treatment was more frequent among the chemoradiotherapy group than the chemotherapy group (16.7% vs. 6.3%, Pa=0.0379). The rate of surgical resection was consequently higher for the induction chemotherapy group compared to the chemoradiotherapy group (72.1% vs. 45.6%, P=0.0005). Conclusions Induction triplet chemotherapy reduced esophageal perforation and increased the resectability of T4 esophageal cancers by combining second-line chemoradiotherapy. This strategy might increase the chance of curative resection for patients with T4 esophageal cancer. J. Surg. Oncol. 2012; 106:441-447. © 2012 Wiley Periodicals, Inc.
UR - http://www.scopus.com/inward/record.url?scp=84865144445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865144445&partnerID=8YFLogxK
U2 - 10.1002/jso.23081
DO - 10.1002/jso.23081
M3 - Article
C2 - 22371189
AN - SCOPUS:84865144445
VL - 106
SP - 441
EP - 447
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 4
ER -